Parker Waichman LLP Headlines by Topic
Byetta
Byetta, Januvia Cancer Risks Debated
Sep 21, 2011
| Parker Waichman LLP
The uncertainty surrounding type 2 diabetes drugs like Byetta and Januvia have prompted calls for more studies of glucagon-like peptide 1...
Study Find Januvia, Byetta Associated with Increased Risk of Pancreatitis, Pancreatic Cancer
Sep 19, 2011
| Parker Waichman LLP
Diabetes drugs that lower blood sugar by promoting the action of a gut hormone called glucagon-like peptide 1 (GLP-1) may increase the risks of both...
Byetta, Victoza Raise More Cancer Fears
Sep 13, 2011
| Parker Waichman LLP
A new study is adding to concerns that type 2 drugs like Byetta and Victoza could increase the likelihood that a patient will develop pancreatitis...
Doctors Reminded of Victoza Thyroid Tumor, Pancreatitis Risks
Jun 14, 2011
| Parker Waichman LLP
It seems many doctors are unaware of the serious side effects that may be associated with the Type II Diabetes drug Victoza. As a result, Novo...
Victoza Report Raises Byetta Safety Questions
Jun 7, 2011
| Parker Waichman LLP
A new report from the Institute for Safe Medicine Practices (ISMP) may raise safety concerns about a new generation of diabetes drugs, including...
Byetta Cancer Lawsuit Filed in Florida
Jun 3, 2011
| Parker Waichman LLP
A Byetta lawsuit filed in Florida last year claims the Type II Diabetes drug caused pancreatic and liver cancer. The Byetta cancer lawsuit...
FDA Says Promotions, Statements by 4 Drug Makers are Misleading
Jan 13, 2010
| Parker Waichman LLP
Four drug makers have received Food & Drug Administration (FDA) warning letters for misleading promotions and statements about their...
Byetta Patients Report Kidney Problems, Label Revised
Nov 3, 2009
| Parker Waichman LLP
The labeling for Byetta, a drug used to treat type 2 diabetes, has been revised to include new safety information about possible kidney function...
Another Byetta Delay
Dec 9, 2008
| Parker Waichman LLP
Federal regulators are extending a review of the diabetes drug Byetta into next year, Forbes.com is reporting. The Food & Drug...
Flagging Byetta Sales Force Job Cuts at Amylin
Nov 12, 2008
| Parker Waichman LLP
Safety concerns surrounding the diabetes drug Byetta have slowed its sales, forcing Amylin Pharmaceuticals to cut a quarter of its work force....
